Glenmark Pharmaceuticals has reported results for the quarter ended June 30, 2011.
The company‘s net profit has registered growth of 19.20% at Rs 72.46 crore for the quarter as compared to Rs 60.79 crore for the corresponding quarter of the previous year. Its total income has increased by 19.14% at Rs 330.78 crore for the Q1FY12 from Rs 277.62 crore for the Q1FY11.
On consolidated basis, the group’s net profit for the quarter ended June 30, 2011 has clocked in 23.20% growth at Rs 210.11 crore as compared to Rs 170.54 crore for the June quarter of the previous fiscal. Its total income has increased by 26.77% to Rs 880.80 crore for the quarter from Rs 694.81 crore for the June quarter of FY11.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: